80 related articles for article (PubMed ID: 16332724)
1. Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells.
McPhillips F; Mullen P; MacLeod KG; Sewell JM; Monia BP; Cameron DA; Smyth JF; Langdon SP
Carcinogenesis; 2006 Apr; 27(4):729-39. PubMed ID: 16332724
[TBL] [Abstract][Full Text] [Related]
2. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer.
McPhillips F; Mullen P; Monia BP; Ritchie AA; Dorr FA; Smyth JF; Langdon SP
Br J Cancer; 2001 Nov; 85(11):1753-8. PubMed ID: 11742498
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profile by inhibiting Raf-1 protein kinase in breast cancer cells.
Mewani RR; Tian S; Li B; Danner MT; Carr TD; Lee S; Rahman A; Kasid UN; Jung M; Dritschilo A; Gokhale PC
Int J Mol Med; 2006 Mar; 17(3):457-63. PubMed ID: 16465392
[TBL] [Abstract][Full Text] [Related]
4. [Inhibition effects of c-erbB-2 and c-raf-1 antisense oligodeoxynucleotides combined transfection on the human ovarian carcinoma transplanted subcutaneously in nude mice].
Wu YZ; Ren QL; Yang SF; Chen XP; Li SL
Zhonghua Fu Chan Ke Za Zhi; 2003 Jun; 38(6):359-61. PubMed ID: 12895380
[TBL] [Abstract][Full Text] [Related]
5. RAF antisense oligonucleotide as a tumor radiosensitizer.
Kasid U; Dritschilo A
Oncogene; 2003 Sep; 22(37):5876-84. PubMed ID: 12947394
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides.
Watson JM; Berek JS; MartÃnez-Maza O
Gynecol Oncol; 1993 Apr; 49(1):8-15. PubMed ID: 8482564
[TBL] [Abstract][Full Text] [Related]
8. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells.
Chan DW; Liu VW; Tsao GS; Yao KM; Furukawa T; Chan KK; Ngan HY
Carcinogenesis; 2008 Sep; 29(9):1742-50. PubMed ID: 18632752
[TBL] [Abstract][Full Text] [Related]
9. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
Shaw TJ; Vanderhyden BC
Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Marampon F; Ciccarelli C; Zani BM
Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
12. Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer.
Li HZ; Wang Y; Gao Y; Shao J; Zhao XL; Deng WM; Liu YX; Yang J; Yao Z
Mol Cancer Res; 2008 Jun; 6(6):917-28. PubMed ID: 18567796
[TBL] [Abstract][Full Text] [Related]
13. Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma.
Huang Y; Hua K; Zhou X; Jin H; Chen X; Lu X; Yu Y; Zha X; Feng Y
Cell Res; 2008 Jul; 18(7):780-91. PubMed ID: 18574502
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation.
Soldatenkov VA; Dritschilo A; Wang FH; Olah Z; Anderson WB; Kasid U
Cancer J Sci Am; 1997; 3(1):13-20. PubMed ID: 9072302
[TBL] [Abstract][Full Text] [Related]
15. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
16. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
17. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
18. Effects of pharmacological concentrations of estrogens on growth of 3AO human ovarian cancer cells.
Li ZB; Chen YX; Zhao JY; Lu J
Yi Chuan Xue Bao; 2006 Sep; 33(9):782-92. PubMed ID: 16980124
[TBL] [Abstract][Full Text] [Related]
19. Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells.
Pirollo KF; Hao Z; Rait A; Ho CW; Chang EH
Biochem Biophys Res Commun; 1997 Jan; 230(1):196-201. PubMed ID: 9020045
[TBL] [Abstract][Full Text] [Related]
20. Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer.
Hua K; Feng W; Cao Q; Zhou X; Lu X; Feng Y
Int J Oncol; 2008 Nov; 33(5):959-67. PubMed ID: 18949358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
